Welch & Forbes’s Dermata Therapeutics DRMA Stock Holding History

Welch & Forbes’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.8K	Hold	20,000	–	–	﹤0.01%	388
2026 Q1	$24.2K	Buy	+20,000	New	+$33.7K	﹤0.01%	368

Other funds holding DRMA

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Advisory Alpha Holland, Michigan $4.08B AUM 20.62% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

MCF Advisors Covington, Kentucky $2.8B AUM 19.11% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Welch & Forbes's DRMA Position: Q2 2026 in Review

Welch & Forbes held its Dermata Therapeutics (DRMA) position steady in Q2 2026 at 20,000 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #388.

Welch & Forbes first reported a position in DRMA in Q1 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold DRMA as of Q2 2026.

Welch & Forbes held 20,000 shares of Dermata Therapeutics worth $25.8K as of Q2 2026.
Welch & Forbes left its Dermata Therapeutics share count unchanged in Q2 2026.
Dermata Therapeutics made up ﹤0.01% of Welch & Forbes's portfolio in Q2 2026, its #388 holding.
Welch & Forbes first reported a position in Dermata Therapeutics in Q1 2026 and has held it in 2 quarters since.
13 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2026.

Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.